A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

November 27, 2023

Primary Completion Date

August 8, 2024

Study Completion Date

August 8, 2024

Conditions
NSCLC
Interventions
DRUG

BMS-986315

Specified dose on specified days

DRUG

Nivolumab

Specified dose on specified days

DRUG

Pemetrexed

Specified dose on specified days

DRUG

Cisplatin

Specified dose on specified days

DRUG

Carboplatin

Specified dose on specified days

DRUG

Paclitaxel

Specified dose on specified days

Trial Locations (8)

2065

Local Institution - 0013, St Leonards

2485

Local Institution - 0021, Tweed Heads

6027

Local Institution - 0032, Joondalup

32763

Local Institution - 0040, Orange City

34711

Local Institution - 0044, Clermont

37219

Local Institution - 0038, Glendale

77090

Local Institution - 0049, Houston

83706

Local Institution - 0058, Boise

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06094296 - A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter